EDIT vs CRSP
EDIT and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEditas Medicine, Inc. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $272.18M | $5.13B |
| P/S | 6.7x | 1460.9x |
| Revenue growth (YoY) | 25.4% | -90.6% |
| Earnings growth (YoY) | 32.5% | -58.8% |
| EBIT margin | -394.9% | -18933.6% |
| ROE | -3631.1% | -33.3% |
| ROIC | — | -32.6% |
| 1y total return | +9.0% | -11.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: EDIT frente a CRSP
| Métrica | EDIT | CRSP |
|---|---|---|
| Valor final | $2.0K | $37.7K |
| Retorno total | -80.1% | +276.6% |
| CAGR | -15.2% | +14.5% |
| Volatilidad | 84.4% | 64.2% |
| Sharpe | 0.16 | 0.47 |
| Sortino | 0.26 | 0.72 |
| Caída máxima | -98.9% | -85.1% |
Basado en 2460 días de negociación comunes, 2016-10-19 → 2026-08-04 · tasa libre de riesgo 3.89% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)